Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

被引：0
|
作者：
Winer, Eric S. [1 ]
Garcia, Jacqueline S. [2 ]
Stone, Richard M. [1 ]
Wadleigh, Martha [1 ]
Luskin, Marlise R. [1 ]
Stahl, Maximilian [3 ]
Chen, Evan C. [1 ]
Leonard, Rebecca [2 ]
Noyes, Alexis [1 ]
Galinsky, Ilene [2 ]
Deshpande, Rashmi [4 ]
Borderies, Pascal [4 ]
O'Neill, Vincent [4 ]
DeAngelo, Daniel J. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Dana Farber Inst, Boston, MA USA
[4] BioXcel Therapeut, New Haven, CT USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186598
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
    Mollgard, Lars
    Nilsson, Lars
    Kjeldsen, Lars
    Dybedal, Ingunn
    Dufva, Inge Hogh
    Garelius, Hege
    Norgaard, Jan Maxwell
    Linder, Olle
    Ejerblad, Elisabeth
    Astermark, Jan
    Hellstrom-Lindberg, Eva
    BLOOD, 2009, 114 (22) : 52 - 52
  • [42] PHASE 2, OPEN-LABEL STUDY OF E7070, IDARUBICIN AND CYTARABINE IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMA AND HIGH-RISK MYELODYSPLASTIC SYNDROME
    Borthakur, G.
    Cortes, J. E.
    Kadia, T. M.
    Pemmaraju, N.
    Jabbour, E.
    Jain, N.
    Daver, N.
    Kantarjian, H.
    HAEMATOLOGICA, 2014, 99 : 34 - 34
  • [43] Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2157 - 2164
  • [44] Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami
    HAEMATOLOGICA, 2024, 109 (07) : 2157 - 2164
  • [45] A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
    Mattison, Ryan
    Jumonville, Alcee
    Flynn, Patrick James
    Moreno-Aspitia, Alvaro
    Erlichman, Charles
    LaPlant, Betsy
    Juckett, Mark B.
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2061 - 2066
  • [46] Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study
    Halpern, Anna B.
    Buckley, Sarah A.
    Othus, Megan
    Huebner, Emily M.
    Orlowski, Kaysey F.
    Scott, Bart L.
    Perdue, Andrea M.
    Smith, Heather A.
    Becker, Pamela S.
    Hendrie, Paul C.
    Cassone, Stephanie
    Chen, Tara L.
    Stirewalt, Derek L.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2016, 128 (22)
  • [47] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [48] Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes
    Roboz, Gail J.
    Yee, Karen
    Verma, Amit
    Borthakur, Gautam
    de la Fuente Burguera, Adolfo
    Sanz, Guillermo
    Mohammad, Helai P.
    Kruger, Ryan G.
    Karpinich, Natalie O.
    Ferron-Brady, Geraldine
    Acusta, Andre
    Del Buono, Heather
    Collingwood, Therese
    Ballas, Marc
    Dhar, Arindam
    Wei, Andrew H.
    LEUKEMIA & LYMPHOMA, 2022, 63 (02) : 463 - 467
  • [49] Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
    Oka, Satoko
    Ono, Kazuo
    CLINICAL CASE REPORTS, 2021, 9 (06):
  • [50] Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
    Cortes, J
    Giles, F
    O'Brien, S
    Thomas, D
    Albitar, M
    Rios, MB
    Talpaz, M
    Garcia-Manero, G
    Faderl, S
    Letvak, L
    Salvado, A
    Kantarjian, H
    CANCER, 2003, 97 (11) : 2760 - 2766
12345